RT Journal Article
SR Electronic
T1 Serum B cell activating factor (BAFF) as a prognostic biomarker in interstitial lung diseases associated with connective tissue diseases
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P720
VO 44
IS Suppl 58
A1 Tsutomu Hamada
A1 Takuya Samukawa
A1 Tomohiro Kumamoto
A1 Ikkou Higashimoto
A1 Keiko Mizuno
A1 Masaki Watanabe
A1 Hiromasa Inoue
YR 2014
UL http://erj.ersjournals.com/content/44/Suppl_58/P720.abstract
AB Background; B cell activating factor (BAFF) is a vital homeostatic cytokine for B cells, and has been associated with autoimmune diseases. We have already shown that the However, the elevation of serum BAFF has not been investigated in patients with interstitial lung diseases associated with connective tissue diseases (CTD-ILD) and idiopathic interstitial pneumonia (IIP). However, BAFF has not been confirmed as a prognostic biomarker for CTD-ILD.Aim; The aim of this study was to investigate the potential of serum BAFF as a prognostic useful biomarker in patients with CTD-ILD.Methods; We evaluated the association between serum BAFF concentrations and mortality in 37 patients with CTD-ILD. 23 healthy volunteers were included as a control group. Serum BAFF levels were measured by ELISA.Results; Serum BAFF levels in serum were significantly elevated in patients with CTD-ILD (2.2±1.1 ng/ml) compared with control subjects (0.7±0.1 ng/ml, p<0.01). We found that increased serum BAFF level (>2.4 ng/ml) was associated with increased risk of mortality (hazard ratio, 15.01; 95% confidence interval, 1.43 to 156.70; p=0.02).Conclusions; Increased serum BAFF level might be a predictor of mortality in patients with CTD-ILD.